In DepthGenome Editing

China sprints ahead in CRISPR therapy race

See allHide authors and affiliations

Science  06 Oct 2017:
Vol. 358, Issue 6359, pp. 20-21
DOI: 10.1126/science.358.6359.20

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

CRISPR, the wildly popular genome-editing research tool, was invented in the West, but it is speeding toward potential human applications in China. Last week, the Chinese team that sparked a worldwide debate in 2015 when it reported the first use of CRISPR to edit a human embryo's genome notched another first. In early embryos, they showed that a new CRISPR variant, which chemically modifies rather than cuts DNA, can correct the mutation causing a debilitating blood disease. But the most striking evidence of progress in China can be found on the clinicaltrials.gov database: Of the 10 listed trials of CRISPR in patients, nine are in China, where streamlined safety and ethical reviews have given researchers a head start. Three of the groups confirmed to Science that they are infusing cancer patients with their own immune cells modified using CRISPR.